|
ALIMTA (pemetrexed) Plus Gemcitabine (Gemzar) for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have not had Previous Chemotherapy. Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on ALIMTA (pemetrexed) Plus Gemcitabine (Gemzar) for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have not had Previous Chemotherapy. conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. ALIMTA (pemetrexed) Plus Gemcitabine (Gemzar) for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have not had Previous Chemotherapy. Clinical research trials and ALIMTA (pemetrexed) Plus Gemcitabine (Gemzar) for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have not had Previous Chemotherapy. healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including ALIMTA (pemetrexed) Plus Gemcitabine (Gemzar) for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have not had Previous Chemotherapy.. ALIMTA (pemetrexed) Plus Gemcitabine (Gemzar) for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have not had Previous Chemotherapy. Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a ALIMTA (pemetrexed) Plus Gemcitabine (Gemzar) for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have not had Previous Chemotherapy. clinical trial. Test subjects typically receive the most effective healthcare possible for their ALIMTA (pemetrexed) Plus Gemcitabine (Gemzar) for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have not had Previous Chemotherapy. condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > ALIMTA (pemetrexed) Plus Gemcitabine (Gemzar) for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have not had Previous Chemotherapy.  ALIMTA (pemetrexed) Plus Gemcitabine (Gemzar) for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have not had Previous Chemotherapy.
ALIMTA (pemetrexed) Plus Gemcitabine (Gemzar) for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have not had Previous Chemotherapy.
For Condition: Carcinoma, Non-Small-Cell Lung
Status: No longer recruiting
Sponsor(s): Eli Lilly and Company ,
Synopsis: The purposes of this study are to determine: 1) The safety of ALIMTA plus Gemcitabine and any side effects that might be associated with the combination of these two drugs. 2) Whether ALIMTA plus Gemcitabine can help patients with non-small cell lung cancer live longer. 3) Whether ALIMTA plus Gemcitabine can make the tumor smaller or disappear, and for how long. 4) To see if patients feel better while taking ALIMTA plus Gemcitabine.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Diagnosis of Non-Small Cell Lung Cancer that can be treated with chemotherapy - Have received no prior chemotherapy for Non-Small Cell Lung Cancer - Have at least one measurable lesion - Have an adequate performance status - Sign an informed consent Exclusion Criteria: - A female who is pregnant or breastfeeding - Treatment with an investigational drug within the last 30 days, previously completed or withdrawn from this study or any other study investigating ALIMTA - Treatment with radiation therapy within the last 1-2 weeks - Brain metastasis that is uncontrolled - Active infection or other serious condition
Total Enrollment:
Location and Contact Information:
For information on a site near you, call our call center at 1-877-CTLILLY(1-877-285-4559)
Columbia, South Carolina,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Miami, Florida,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Shreveport, Louisiana,
United States
For information on a site near you, call our call center at 1-877-CTLILLY(1-877-285-4559)
Philadelphia, Pennsylvania,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Chicago, Illinois,
United States
For information on a site near you, call our call center at 1-877-CTLILLY(1-877-285-4559)
Ft. Myers, Florida,
United States
Additional Information:
Study ID Numbers: 7211;
Study Start Date:
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00061464
Other Carcinoma, Non-Small-Cell Lung Studies:
1. A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin versus Gemcitabine and Cisplatin in Patients with Advanced, Previously Untreated Non-Small Cell Lung Cancer
2. Study of Cetuximab in Combination with Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer
3. This study is to assess the efficacy and safety of ZD6474 in subjects with Non-small cell lung cancer.
4. Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer
5. A Phase 3 Randomized Study of Lonafarnib in Combination With Paclitaxel and Carboplatin vs. Placebo in Combination with Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer
Related Studies:
Other Carcinoma, Non-Small-Cell Lung Clinical Trials
Other Florida Clinical Trials
Other Ft. Myers Clinical Trials
ALIMTA (pemetrexed) Plus Gemcitabine (Gemzar) for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have not had Previous Chemotherapy.
|
|
|
|
|
|
|
|
